Ethris

Focus: Ethris is a German biotech company specializing in mRNA-based therapies and vaccines across infectious diseases, gene therapy, and vaccine development. The company operates as a focused pre-revenue biotech with early-stage pipeline assets.

Infectious Diseases Gene Therapy Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Ethris

AI assessmentNot Hiring

No open roles listed right now. Follow Ethris to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ETH47

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT07055321A Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants

Phase 1

Help build intelligence for Ethris

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Frontier mRNA platform with applications across infectious diseases, gene therapy, and vaccines—emerging modality with high upside potential
Early-stage company offers meaningful impact on drug discovery and development with hands-on involvement across multiple therapeutic areas
German biotech base provides access to strong European academic networks and regulatory infrastructure

Watch Out For

Pre-revenue stage with unknown funding trajectory and cash runway creates uncertainty around job security and growth capacity
Minimal pipeline visibility: only 2 active trials (Phase 1/2) with limited clinical data and no near-term regulatory catalysts
Zero current open positions and no disclosed hiring activity suggest limited near-term career movement or promotion velocity

Generated by Claude from Ethris's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ETH47

Asthma (Diagnosis)

Phase 2

Clinical Trials (1)

NCT07059767Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Respiratory

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Respiratory

1 pipeline

Marketed

Pipeline